Myeloid immune-checkpoint inhibition enters the clinical stage
- 20 December 2018
- journal article
- editorial
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 16 (5) , 275-276
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Immune Effector Functions of Human IgG2 Antibodies against EGFRMolecular Cancer Therapeutics, 2019
- CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s LymphomaNew England Journal of Medicine, 2018
- Neutrophils Kill Antibody-Opsonized Cancer Cells by TrogoptosisCell Reports, 2018
- The CD47‐SIRPα signaling axis as an innate immune checkpoint in cancerImmunological Reviews, 2017
- Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic PotentialPLOS ONE, 2015
- CD47 blockade triggers T cell–mediated destruction of immunogenic tumorsNature Medicine, 2015
- CD47–signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destructionProceedings of the National Academy of Sciences, 2011
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin LymphomaCell, 2010
- Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclassesBlood, 2009
- Role of CD47 as a Marker of Self on Red Blood CellsScience, 2000